Single Use Bioreactor Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Single Use Bioreactor Market Report is Segmented by Product (Single-Use Bioreactor Systems, Media Bags, and More), Cell Type (Mammalian, Bacterial, and More), Molecule Type (Monoclonal Antibodies, Vaccines, and More), End User (Biopharma & Pharma Manufacturers, and More), Geography (North America, Europe, Asia-Pacific, The Middle East and Africa, and South America). The Market Forecasts are Provided in Terms of Value (USD).

Single-use Bioreactor Market Size and Share

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Compare market size and growth of Single-use Bioreactor Market with other markets in Healthcare Industry

Single-use Bioreactor Market Analysis by Mordor Intelligence

The single-use bioreactor market generated USD 4.74 billion in 2025 and is on course to reach USD 8.28 billion by 2030, reflecting a 14.99% CAGR. Growth hinges on biopharma’s preference for flexible, rapidly deployable facilities, stringent regulatory expectations for sterility, and the surge in advanced therapies that demand smaller batch runs. Capacity additions by leading CDMOs, rising vaccine programs structured around platform technologies, and investors’ appetite for modular plants strengthen the revenue outlook. Cost efficiency over stainless-steel systems, lower contamination risk, and shorter turnaround times continue to widen adoption. Sustainability initiatives around bio-based films and circular-economy recycling schemes also influence procurement strategies.

Key Report Takeaways

  • By scale, commercial-scale systems (500–2,000 L) led with 52.44% of the single-use bioreactor market share in 2024, while pilot-scale units (50–500 L) are rising at a 17.11% CAGR to 2030.
  • By product category, single-use bioreactor systems held 41.45% revenue share in 2024; filtration assemblies are forecast to expand at a 16.65% CAGR through 2030.
  • By cell type, mammalian applications captured 62.34% of the single-use bioreactor market size in 2024, yet yeast systems are growing fastest at a 15.89% CAGR.
  • By molecule type, monoclonal antibodies accounted for 45.21% share of the single-use bioreactor market size in 2024; stem-cell applications advance at a 16.87% CAGR.
  • By region, North America controlled 41.45% of 2024 revenue; Asia-Pacific is projected to post the highest 15.67% CAGR through 2030.

Segment Analysis

By Product: Single-Use Systems Drive Innovation

Single-use bioreactor systems delivered 41.45% of 2024 revenue, solidifying their status as the backbone of the single-use bioreactor market. Filtration assemblies, however, record the fastest 16.65% CAGR as regulators heighten scrutiny over particulate and viral clearance. This momentum reflects broader integration of upstream and downstream disposables into closed, sterile trains. Media bags post steady gains, enabling ready-made medium formulation that trims lead times by weeks. Sensors migrate from reusable probes to pre-calibrated single-use formats that embed directly in the reactor bag, enhancing automation. Asahi Kasei’s Planova™ FG1 filter, seven-times more permeable than prior versions, underscores that filtration breakthroughs can unlock higher titers without process redesign.

The decade-long expansion shows penetration leaping from roughly 35% in 2020 to a projected 75% by 2030. Thermo Fisher’s 5 L DynaDrive reactor lifts productivity 27% and scales linearly to 5,000 L, bridging lab to plant and accelerating tech-transfer cycles. New biobased multilayer films lessen landfill burden while preserving oxygen and CO₂ permeability. Collectively, these innovations guarantee that the single-use bioreactor market will sustain double-digit expansion through the forecast horizon.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Cell Type: Mammalian Dominance with Emerging Opportunities

Mammalian platforms held 62.34% of 2024 turnover, anchored by Chinese hamster ovary (CHO) production of monoclonal antibodies. Yet yeast cultures are rising at a 15.89% CAGR as glyco-optimized strains match mammalian glycosylation patterns at lower cost. Bacterial fermentation maintains relevance for recombinant enzymes and plasmid supply. Stem-cell processing matures in parallel, supported by closed perfusion formats that safeguard sterility for autologous therapies.

Daewoong Bio’s Hwaseong plant adds microbial capacity to diversify beyond CHO and capture biosimilar demand. Recent perfusion runs hit 49 million cells/mL and titers of 5.2 g/L, cementing mammalian output gains. The single-use bioreactor market size attributed to mammalian lines will therefore climb even as niche cell types carve share in emerging modalities.

By Molecule Type: Antibodies Lead, Stem Cells Surge

Monoclonal antibodies secured 45.21% of the 2024 single-use bioreactor market size, supported by new oncology, autoimmune, and infectious-disease launches. Stem-cell therapies, bolstered by gene-edited and iPSC approaches, expand at 16.87% CAGR, relying on closed, disposable reactors that minimize contamination risk. Vaccines retain prominence amid pandemic preparedness funding, while recombinant proteins stay resilient across endocrine, metabolic, and enzyme-replacement franchises.

Believer Meats’ tie-up with GEA to engineer 25 L reactors for cultivated meat shows how bioreactor design knowledge spills into non-pharma fields. The single-use bioreactor market will therefore widen beyond therapeutic biologics into food-tech, cosmetics, and industrial biotech applications over the next decade.

By Bioreactor Design: Stirred-Tank Systems Dominate

Stirred-tank formats captured 48.54% revenue in 2024 by balancing mixing, oxygen transfer, and scale-up fidelity. Fixed-bed units grow quickest at 16.43% CAGR, tailored for adherent cell lines required in gene therapy or vaccine vector production. Wave-mixed bags hold a niche for shear-sensitive cells, while orbitally shaken vessels serve analytical and seed-train duties.

Cytiva’s iCELLis fixed-bed system boosts adherent culture density through patented waterfall oxygenation, yielding higher volumetric productivity with a smaller cleanroom footprint[2]Cytiva, “iCELLis Fixed-Bed Bioreactor Fact Sheet,” cytivalifesciences.com. Incremental design gains will keep stirred tanks in pole position but alternative topologies will carve out application-specific growth pockets inside the single-use bioreactor market.

By Scale: Commercial-Scale Leadership with Pilot Growth

Commercial volumes (500–2,000 L) represented 52.44% of 2024 turnover, offering the sweet spot where economies of scale meet multiproduct flexibility. Pilot-scale units expand fastest at 17.11% CAGR as biotechs validate processes and CDMOs standardize 200–500 L suites for parallel trials. Lab-scale systems remain foundational for discovery and pre-clinical runs, while large-scale (>2,000 L) reactors anchor legacy blockbuster antibodies.

Fujifilm Diosynth’s decision to install arrays of 20,000 L units rather than one mega-vessel allows modular build-out as demand unfolds. The strategy illustrates how capacity planners optimize utilization and sidestep the downtime associated with giant upstream equipment.

Single Use Bioreactor Market
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By End User: Biopharma Leads, CDMOs Accelerate

Biopharma and pharmaceutical companies commanded 58.54% revenue in 2024, reflecting direct product commercialization. CDMOs/CROs chart the fastest 17.65% CAGR, providing turnkey capacity for firms choosing capital-light models. Academic institutes and government labs absorb systems for process development, but volumes remain modest.

AGC Biologics introduced Cytiva FlexFactory suites in Yokohama to support mRNA vaccines and antibodies, confirming that CDMOs select standardized single-use footprints to pivot between modalities. As outsourcing progresses, the single-use bioreactor industry will further entrench CDMOs as pivotal capacity holders.

Geography Analysis

North America retained 41.45% of 2024 revenue as CDMOs and pharma majors expanded disposable capacity. Fujifilm Diosynth’s USD 1.2 billion North Carolina extension and Novo Nordisk’s USD 4.1 billion Clayton site underscore the region’s commitment to agile biologics supply. Academic-industry consortia and reliable venture funding round out supportive infrastructure.

Asia-Pacific exhibits the quickest 15.67% CAGR. China’s biomanufacturing self-reliance plan funds large-scale single-use lines, while India leverages established formulation expertise to target biosimilar exports. South Korea’s Daewoong Bio added GMP microbial suites, reflecting higher regional specialization. Talent development and local reagent supply chains remain priorities to sustain momentum.

Europe advances steadily as sustainability legislation pushes producers toward recyclable bags and bio-based films. Boehringer Ingelheim’s USD 811 million Vienna facility integrates end-to-end digital twins and smart sensors, demonstrating adherence to Industry 4.0 paradigms. Germany’s Rentschler invests in buffer-media infrastructure to shore up supply resilience, enhancing the appeal of European outsourcing for global drug sponsors.

Single Use Bioreactor Market
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

Sartorius, Thermo Fisher Scientific, and Cytiva together held just over 45% of 2024 revenue, reflecting wide portfolios that bundle reactors, bags, sensors, and validation services. These firms deepen global footprints via acquisitions and regional manufacturing hubs that shorten lead times. Sartorius’ purchase of Biological Industries secured in-house media capabilities that complement its bag-and-filter catalog.

Technology differentiation intensifies around niche modalities. Ever After Foods partners with Bühler on edible packed-bed reactors that cut media demand by 90% for cultivated meat output[3]FoodNavigator-USA, “Ever After Foods Partners with Bühler,” foodnavigator-usa.com. Competition thus extends beyond classical pharma into food and cosmetic bioprocessing, widening addressable markets.

Strategic alliances between equipment manufacturers and drug sponsors hasten commercial-scale proof. GEA’s collaboration with Believer Meats on bespoke reactors typifies co-innovation that reduces risk and accelerates design finalization. Providers selling ecosystem-style packages—hardware plus digital twins, analytics, and maintenance—build switching costs and recurring consumable revenue that underpin margin resilience.

Single-use Bioreactor Industry Leaders

  1. Sartorius AG

  2. Thermo Fisher Scientific, Inc.

  3. Danaher (Cytiva & Pall)

  4. Merck KGaA

  5. Eppendorf SE

  6. *Disclaimer: Major Players sorted in no particular order
Single Use Bioreactor Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • January 2025: Fujifilm Diosynth Biotechnologies reported over USD 8 billion invested to double Hillerød capacity and add six mammalian bioreactors.
  • January 2025: Rentschler Biopharma declared its Massachusetts line fully operational, expanding single-use GMP throughput.
  • November 2024: Sartorius Stedim Biotech opened the Center for Bioprocess Innovation in Marlborough with two GMP suites.
  • November 2024: Avid Bioservices accepted a USD 1.1 billion buyout by GHO Capital and Ampersand Capital to scale CDMO services.
  • October 2024: Rentschler Biopharma began building a 34,000 m² buffer-media plant in Laupheim, Germany.

Table of Contents for Single-use Bioreactor Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Drivers
    • 4.1.1 Growing Biologics Manufacturing Demand
    • 4.1.2 Cost and Flexibility Advantages of Single-Use Systems
    • 4.1.3 Rising Contract Manufacturing Outsourcing
    • 4.1.4 Accelerated Vaccine Development Timelines
    • 4.1.5 Sustainability Initiatives For Bio-Based Single-Use Materials
    • 4.1.6 Decentralized Modular Bioprocessing Facilities
  • 4.2 Market Restraints
    • 4.2.1 High Recurring Consumable Expenditure
    • 4.2.2 Regulatory Scrutiny of Extractables And Leachables
    • 4.2.3 Environmental Concerns Over Disposable Plastic Waste
    • 4.2.4 Scale-Up Limitations In High-Volume Commercial Production
  • 4.3 Regulatory Landscape
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. Market Size & Growth Forecasts (Value, USD)

  • 5.1 By Product
    • 5.1.1 Single-Use Bioreactor Systems
    • 5.1.2 Media Bags
    • 5.1.3 Filtration Assemblies
    • 5.1.4 Other Products
  • 5.2 By Cell Type
    • 5.2.1 Mammalian
    • 5.2.2 Bacterial
    • 5.2.3 Yeast
    • 5.2.4 Other Cell Types
  • 5.3 By Molecule Type
    • 5.3.1 Monoclonal Antibodies
    • 5.3.2 Vaccines
    • 5.3.3 Stem Cells
    • 5.3.4 Recombinant Proteins
    • 5.3.5 Other Molecule Types
  • 5.4 By Bioreactor Design
    • 5.4.1 Stirred-Tank
    • 5.4.2 Wave-Mixed
    • 5.4.3 Orbitally Shaken
    • 5.4.4 Fixed-Bed
  • 5.5 By Scale
    • 5.5.1 Lab-Scale (<50 L)
    • 5.5.2 Pilot-Scale (50-500 L)
    • 5.5.3 Commercial-Scale (500-2 000 L)
    • 5.5.4 Large-Scale (>2 000 L)
  • 5.6 By End User
    • 5.6.1 Biopharma & Pharma Manufacturers
    • 5.6.2 CDMOs/CROs
    • 5.6.3 Academic & Research Institutes
    • 5.6.4 Other End Users
  • 5.7 Geography
    • 5.7.1 North America
    • 5.7.1.1 United States
    • 5.7.1.2 Canada
    • 5.7.1.3 Mexico
    • 5.7.2 Europe
    • 5.7.2.1 Germany
    • 5.7.2.2 United Kingdom
    • 5.7.2.3 France
    • 5.7.2.4 Italy
    • 5.7.2.5 Spain
    • 5.7.2.6 Rest of Europe
    • 5.7.3 Asia-Pacific
    • 5.7.3.1 China
    • 5.7.3.2 Japan
    • 5.7.3.3 India
    • 5.7.3.4 Australia
    • 5.7.3.5 South Korea
    • 5.7.3.6 Rest of Asia-Pacific
    • 5.7.4 Middle East & Africa
    • 5.7.4.1 GCC
    • 5.7.4.2 South Africa
    • 5.7.4.3 Rest of Middle East & Africa
    • 5.7.5 South America
    • 5.7.5.1 Brazil
    • 5.7.5.2 Argentina
    • 5.7.5.3 Rest of South America

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes Global-level Overview, Market-level Overview, Core Segments, Financials, Strategic Information, Market Rank/Share, Products & Services, Recent Developments)
    • 6.3.1 ABEC
    • 6.3.2 Applikon (Getinge)
    • 6.3.3 Cellexus
    • 6.3.4 Celltainer
    • 6.3.5 Danaher (Cytiva & Pall)
    • 6.3.6 Eppendorf SE
    • 6.3.7 GE Healthcare
    • 6.3.8 Lonza
    • 6.3.9 Merck KGaA
    • 6.3.10 OmniBRx Biotechnologies
    • 6.3.11 Pall Corporation
    • 6.3.12 PBS Biotech
    • 6.3.13 Sartorius AG
    • 6.3.14 Thermo Fisher Scientific, Inc.
    • 6.3.15 Univercells
    • 6.3.16 WuXi Biologics

7. Market Opportunities & Future Outlook

  • 7.1 White-Space & Unmet-Need Assessment
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Global Single-use Bioreactor Market Report Scope

As per the scope of the report, single-use bioreactors (SUBs), also known as disposable bioreactors, have now become an integral part of biotechnology manufacturing facilities. The single-use bioreactor market is segmented by Type of Product (Single-use Bioreactor Systems, Media Bags, Filtration Assemblies, and Other Products), Cell Type (Mammalian Cell, Bacteria, Yeast, and Other Cell Types), Molecule Type (Vaccines, Monoclonal Antibodies, Stem Cells, Recombinant Proteins and Other Molecule Types), End User (Pharmaceutical and Biopharmaceutical Industries, Contract Research Organizations (CRO) and Other End Users), and Geography (North America, Europe, Asia Pacific, Middle East, and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

By Product Single-Use Bioreactor Systems
Media Bags
Filtration Assemblies
Other Products
By Cell Type Mammalian
Bacterial
Yeast
Other Cell Types
By Molecule Type Monoclonal Antibodies
Vaccines
Stem Cells
Recombinant Proteins
Other Molecule Types
By Bioreactor Design Stirred-Tank
Wave-Mixed
Orbitally Shaken
Fixed-Bed
By Scale Lab-Scale (<50 L)
Pilot-Scale (50-500 L)
Commercial-Scale (500-2 000 L)
Large-Scale (>2 000 L)
By End User Biopharma & Pharma Manufacturers
CDMOs/CROs
Academic & Research Institutes
Other End Users
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa GCC
South Africa
Rest of Middle East & Africa
South America Brazil
Argentina
Rest of South America
By Product
Single-Use Bioreactor Systems
Media Bags
Filtration Assemblies
Other Products
By Cell Type
Mammalian
Bacterial
Yeast
Other Cell Types
By Molecule Type
Monoclonal Antibodies
Vaccines
Stem Cells
Recombinant Proteins
Other Molecule Types
By Bioreactor Design
Stirred-Tank
Wave-Mixed
Orbitally Shaken
Fixed-Bed
By Scale
Lab-Scale (<50 L)
Pilot-Scale (50-500 L)
Commercial-Scale (500-2 000 L)
Large-Scale (>2 000 L)
By End User
Biopharma & Pharma Manufacturers
CDMOs/CROs
Academic & Research Institutes
Other End Users
Geography
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa GCC
South Africa
Rest of Middle East & Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

What is the projected value of the single-use bioreactor market by 2030?

The market is forecast to reach USD 8.28 billion by 2030 on a 14.99% CAGR trajectory.

Which region will grow fastest in disposable bioreactors?

Asia-Pacific is expected to post the highest 15.67% CAGR through 2030 on the back of Chinese and Indian capacity build-outs.

Why do CDMOs favor single-use reactors?

CDMOs serve multiple clients and products, and disposable systems minimize cross-contamination risk while enabling quick changeovers that maximize asset utilization.

How are regulators influencing technology selection?

Stricter extractables and leachables standards push buyers toward certified low-E&L films and drive investment in analytical validation capabilities.

Which product sub-segment is expanding most quickly?

Filtration assemblies are growing at a 16.65% CAGR due to intensified viral and particulate clearance requirements.

Are single-use reactors sustainable?

Suppliers are introducing bio-based films and recycling programs, and although consumable waste remains a concern, lifecycle assessments often show lower water and energy footprints than stainless-steel systems.

Single-use Bioreactor Market Report Snapshots